Endometrial Carcinoma with Pleural Metastasis

Semczuk, Andrzej; Skomra, Danuta; Rybojad, Paweł; Jęczeń, Ryszard; Rechberger, Tomasz

doi:10.1159/000326045

Cited by 12 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we noted the same immunohistochemical staining pattern of different monoclonal antibodies in both tumors studied, confirming the origin of inquinal metastases from primary carcinoma of the clitoris [18]. Moreover, we reported on pleural metastasis of a highly-aggressive subtype of EC-serous papillary carcinoma, negative for estrogen and progesterone receptors and showing MIB-1 PI (Proliferative Index) in 19% of neoplastic cells [22]. In the present study, we tried to assess P53/MDM2 overexpression in primary and metastatic ECs, placing special emphasis on the relationship, if any, between overexpression of proteins and clinico-prognostic features of cancer.…”

Section: Discussionsupporting

confidence: 82%

“…Data obtained by our laboratory suggest that immunohistochemical assessment of cell cycle-associated molecules may yield clues as to the pathogenesis of disseminated neoplasms from the female genital tract tumors [18,22]. In a previous study, we noted the same immunohistochemical staining pattern of different monoclonal antibodies in both tumors studied, confirming the origin of inquinal metastases from primary carcinoma of the clitoris [18].…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

Jęczeń¹,

Skomra

Cybulski

et al. 2007

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

Several studies have reported that p53/mdm2 distortions play a pivotal role in the development and progression of various human malignancies. However, the number of reports having evaluated simultaneously the components of the P53-pathway alterations in advanced-stage human endometrial carcinomas (EC) is low. In this study, we examined the expression of P53/MDM2 proteins in primary and metastatic ECs, and analyzed the clinicopathological characteristics as well as the survival outcome of patients in relation to P53/MDM2 overexpression. The study group comprised 36 patients with advanced EC, whose primary and metastatic tumor slides were sufficient for analysis. Immunohistochemical assessment was made by applying anti-human P53 and MDM2 antibodies and a highly sensitive EnVision(+)/HPR visualization system. Nuclear P53 overexpression was seen in 11 (31%) primary ECs and 12 (33%) metastatic tumors. There was a significant correlation between P53 overexpression (in primary cancers and metastatic tumors) and MDM2 overexpression in metastatic tumors. Nuclear MDM2 overexpression was noted in 42% (15/36) of primary carcinomas and in 47% (17/36) of metastatic tumors. A significant association existed between MDM2 overexpression and histological grading (G1 + G2 versus G3, P = 0.043). P53/MDM2 overexpression occurred simultaneously in 7 out of 36 (19%) primary ECs and in 9 out of 36 (25%) metastatic lesions. Concomitant overexpression of these proteins was reported in 7 out of 36 (19%) cases and tended to be higher in tumors showing VSI compared to neoplasms lacking vascular space invasion (P = 0.051). P53 overexpression, either in primary ECs (P < 0.0001) or metastatic lesions (P < 0.0001), was significantly associated with poor survival in univariate analysis. Moreover, the log-rank test demonstrated that simultaneous P53/MDM2 overexpression was also correlated with decreased length of survival. There was no correlation between MDM2 overexpression and patient survival. Multivariate Cox regression analysis revealed that only P53 overexpression is an independent predictor of survival. In conclusion, our data support the view that patients with P53 overexpression are significantly associated with an unfavorable outcome, whereas MDM2 overexpression is not related to decreased survival length in women operated on for advanced-stage EC.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 74%

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

Jęczeń¹,

Skomra

Cybulski

et al. 2007

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…9,10,14Y16 Previously, a similar pattern of immunohistochemical markers in primary papillary serous EC and corresponding pleural metastases has been reported. 14 Our data showed that p53/MDM2 overexpression tended to be higher in tumors demonstrating VSI compared with neoplasms lacking VSI. 9 Moreover, the development of EC metastases correlated significantly with the p16 genetic alterations being reported in 93% and 58% of primary ECs with and without metastases, respectively.…”

Section: Discussionmentioning

confidence: 47%

The Pattern of p14^ARF Expression in Primary and Metastatic Human Endometrial Carcinomas

Olcha¹,

Cybulski²,

Skomra

et al. 2010

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fine-needle aspiration diagnosis of metastatic endometrial carcinoma to sites other than bone have been reported,[ 51 52 53 54 55 56 57 58 ] including abdominal wall, breast, pleura, pancreas, tongue, and thyroid. Most of these metastatic tumors were endometrioid carcinomas, with some serous papillary cancers and a few clear cell carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Tibial bone metastasis as an initial presentation of endometrial carcinoma diagnosed by fine-needle aspiration cytology: A case report and review of the literature

et al. 2015

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecologic malignancy in the United States. However, bony metastasis is infrequent and exceptionally rare as the initial presentation. We report a case of a 77-year-old female with a clinically silent endometrial carcinoma who presented with a left tibial metastasis as the first manifestation of her disease. Ours is only the third case diagnosed by fine-needle aspiration (FNA) cytology, and the first to detail the cytomorphologic features of metastatic endometrial cancer to bone. These microscopic findings, including three-dimensional cohesive clusters with cellular overlapping and cuboidal to columnar cells exhibiting low nuclear: cytoplasmic ratios and partially vacuolated cytoplasm, differ significantly from those of endometrial carcinoma on a Papanicolaou test. The tumor bore similarity to the more commonly encountered metastatic colon cancer, but immunohistochemical staining enabled reliable distinction between these entities. A review of osseous metastases of endometrial cancer demonstrates a predilection for bones of the lower extremity and pelvis with a predominance of the endometrioid histologic subtype. In about a quarter of the cases, the bony metastasis was the first manifestation of the cancer. FNA was an effective diagnostic modality for this unusual presentation of a common malignancy. Awareness of this entity and its differential diagnosis is essential for accurate and timely diagnosis.

show abstract

Endometrial Carcinoma with Pleural Metastasis

Cited by 12 publications

References 17 publications

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

The Pattern of p14^ARF Expression in Primary and Metastatic Human Endometrial Carcinomas

Tibial bone metastasis as an initial presentation of endometrial carcinoma diagnosed by fine-needle aspiration cytology: A case report and review of the literature

Contact Info

Product

Resources

About

Endometrial Carcinoma with Pleural Metastasis

Cited by 12 publications

References 17 publications

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome

The Pattern of p14ARF Expression in Primary and Metastatic Human Endometrial Carcinomas

Tibial bone metastasis as an initial presentation of endometrial carcinoma diagnosed by fine-needle aspiration cytology: A case report and review of the literature

Contact Info

Product

Resources

About

The Pattern of p14^ARF Expression in Primary and Metastatic Human Endometrial Carcinomas